Saturday, June 5, 2010

OncoLink at ASCO
OncoLink reporters provide in-depth coverage of scientific presentations from the 46th Annual ASCO Meeting.


A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study Contrasting effects of religious/spiritual support from religious communities versus medical teams on advanced cancer patient end-of-life care Effect of YOCAS yoga on sleep, fatigue, and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ) Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm) Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study

Keywords

Click on any of these terms for more related articles

Blogs

Don't Assume You Understand
by Bob Riter
July 29, 2015

Related News

Developments in Hematology & Oncology for October 2010

Nov 2, 2010

Developments in Hematology & Oncology for October 2010


ASCO: Rx Strategies Promising for CLL, Non-Hodgkin's Lymphoma

Jun 2, 2015

Ibrutinib, obinutuzumab slow progression of CLL, non-Hodgkin's lymphoma


Number of laws to obstruct localities from setting more stringent restrictions has decreased

Feb 9, 2010

Number of laws to obstruct localities from setting more stringent restrictions has decreased